Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03394781 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
A Phase 2 study, sponsored by Durect.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03394781 is a Phase 2 study that was terminated before completion, run by Durect. The registered enrollment target is 5 participants.
The verdict
NCT03394781, a Phase 2 study, was terminated before completion, sponsored by Durect.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).
Interventions
- DRUG DUR-928
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03394781
The ClinicalTrials.gov registry entry for NCT03394781 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durect, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DUR-928 is the first listed.
NCT03394781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03394781 about?
NCT03394781 is a clinical study titled "A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)". This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).
What is the current status of trial NCT03394781?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-01-22. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT03394781?
The interventions under investigation include: DUR-928 (DRUG).
Who is sponsoring clinical trial NCT03394781?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.